Korea Approves Second Biosimilar Infliximab
This article was originally published in PharmAsia News
After receiving the green light for its version of etanercept a few months ago, Samsung Bioepis has gained a second biosimilar regulatory approval in South Korea as it aims to catch up with frontrunner Celltrion. Renflexis is the second infliximab biosimilar to be approved in the country after Celltrion's Remsima.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.